Webinar

ADC Nonclinical DMPK and Safety Strategies: From Discovery to Translation

September 16, 2026 | 11:00 AM EST / 5:00 PM CET

Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with highly potent payloads via chemical linkers, creating unique challenges for nonclinical pharmacokinetics and pharmacodynamics (PK/PD), and safety evaluation.

Key hurdles include linker stability, payload release kinetics, in vivo PK/PD, biodistribution, and target-mediated & payload-driven toxicity—all of which require carefully designed DMPK and toxicological approaches.

This webinar presents a systematic, tiered nonclinical DMPK‑Tox strategy that addresses these challenges from discovery to IND. 

Register Now

In this webinar, you'll learn:

• Distinct ADC characteristics and their impact on DMPK and toxicity study design.
  
  
• A comprehensive study framework – integrating in vitro stability/metabolism assays, in vivo PK/PD and humanized modeling, exploratory Tox studies with GEMM and NHP model.
  
  
• Cross‑platform integration – bridging bioanalytical data (total/conjugated antibody, free payload, DAR monitoring, ADA), and translational biomarker to enable human dose projection and risk assessment.
  
  
• Case examples illustrating how this integrated approach has successfully advanced ADC candidates from discovery into the clinic.

Register Now

This session offers integrated de‑risking and translational strategies, equipping discovery and development scientists with robust data packages to navigate ADC nonclinical challenges.

About The Presenter:

Dr. Xiaolong Tu, Senior Director, DMPK‑Tox Platform, Crown Bioscience

Dr. Xiaolong Tu earned his Ph.D. from Nanjing University School of Life Sciences in 2016. He now leads the DMPK‑Tox Platform at Crown Bioscience, overseeing integrated DMPK and bioanalytical services. With over a decade of experience in preclinical oncology drug development, he has managed a wide range of programs including ADCs, biologics, and novel modalities. His expertise encompasses nonclinical PK/PD, toxicology and translational oncology. Dr. Tu is dedicated to delivering high‑quality, regulatory‑ready data that bridge discovery and clinical development.